Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study of the ACRYSOF® IQ Extended Depth of Focus Intraocular Lens (IOL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Best Corrected Distance Visual Acuity (BCDVA) of 0.3 logarithm of the minimum angle of resolution (logMAR) (20/40 Snellen) or worse either with or without a glare source present (e.g., Brightness Acuity Tester)~* Preoperative regular astigmatism of \< 1.0 D in both eyes~* Clear intraocular media other than cataract~* Diagnosed with cataract in both eyes~* Planned cataract removal by routine small incision surgery~* Calculated lens power between 18.0 and 25.0 diopter (D) \[when targeted for emmetropia (0.0 D)\]~* Willing and able to complete all required postoperative visits~* Able to comprehend and sign an ethics committee-approved statement of informed consent~* Potential postoperative BCDVA of 0.2 logMAR (20/32 Snellen) or better in each eye based on Investigator's medical opinion.~Exclusion Criteria:~* History of eye pathology and/or inflammation, as specified in the protocol~* Clinically significant/severe ocular surface disease that would affect study measurements based on Investigator expert medical opinion~* History of previous intraocular or corneal surgery~* Pregnant/lactating or has another condition with associated fluctuation of hormones that could lead to refractive changes~* Taking systemic medications that in the Investigator's best medical judgment may confound the outcome or increase the risk to the subject.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DFT015 (Type: EXPERIMENTAL): ACRYSOF® IQ Extended Depth of Focus Intraocular lens (IOL), bilateral implantation
- SN60WF (Type: ACTIVE_COMPARATOR): ACRYSOF® IQ Monofocal IOL, bilateral implantation

Based on this trial design, predict the completion outcome and termination type (if applicable).